ABOUT
Blood Cell Technologies, LLC is an early-stage research and development biopharmaceutical company and resident of JLABS@NYC. We are focused on the identification, validation and commercialization of novel drug targets and compounds that may be used to diagnose or treat disease. This is accomplished by identifying novel cellular targets, targeted drug development and novel biomarker development. Areas of interest include hematology, metabolism, antioxidants and cancer.
INNOVATION
BCT has identified and validated a novel target, biliverdin IXβ reductase (BLVRB), for enhancing platelet production in humans for the treatment of thrombocytopenia. We have developed two classes of small molecule BLVRB inhibitors that enhance megakaryocyte/platelet formation by inhibiting redox coupling during early stages of erythroid/megakaryocyte lineage specification. This is a previously uncharacterized regulatory pathway of megakaryocyte development and enhanced platelet production that would theoretically bypass the toxicities of current thrombocytopenia therapeutics.
